Straits Times Index
3,303.26 -10.79 (-0.33%) S&P 500
5,308.13 +4.86 (+0.09%) Dow
39,806.77 -196.82 (-0.49%) Nasdaq
16,794.88 +108.91 (+0.65%) Bitcoin USD
70,972.89 +4,031.16 (+6.02%) CMC Crypto 200
1,526.51 +37.96 (+2.55%)
GOSS May 2024 2.000 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 2.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 285 |
Business WireGossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
SAN DIEGO, May 14, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California.
Business WireGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 10, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective May 8, 2024, to three new non-executive employees of non-qualified stock option awar
Business WireGossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, May 07, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.
